<DOC>
	<DOCNO>NCT01930890</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability BIIB023 participant lupus nephritis ( LN ) .</brief_summary>
	<brief_title>BIIB023 Long-Term Extension Study Subjects With Lupus Nephritis</brief_title>
	<detailed_description>This extension study participant complete study 211LE201 ( NCT01499355 ) Week 52 discontinue BIIB023 placebo . Eligible participant Study 211LE201 follow 108 week . Participants receive BIIB023 low dose high dose 211LE201 continue receive dosing study ( 211LE202 ; NCT01930890 ) addition background therapy . Participants receive placebo 211LE201 randomize receive either BIIB023 low dose high dose addition background therapy .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Key Subjects complete Week 52 Study 211LE201 ( NCT01499355 ) discontinue BIIB023 placebo study treatment . Subjects childbearing potential must practice effective contraception study willing able continue contraception 6 month last dose study treatment . Key Any significant change medical history subject Study 211LE201 , include laboratory test current clinically significant condition , opinion Investigator , would exclude subject ' participation . The Investigator must rereview subject 's medical fitness participation consider disease would preclude treatment protocol . Subjects Study 211LE201 discontinue BIIB023 placebo treatment prior Week 52 Study 211LE201 . Female subject consider become pregnant study , currently pregnant , breast feeding . Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply protocol . Other unspecified reason , opinion Investigator Biogen , make subject unsuitable enrollment . NOTE : Other Protocoldefined Inclusion/Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>